surmount-1 trial tirzepatide weight loss nondiabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Gastrointestinal tolerability and weight reduction

Mechanism Comparison Source: FDA Prescribing Information Weight Loss Results Head-to-Head Trial The SURMOUNT-5 trial published in the New England Journal of Medicine represents the first direct comparison between these new weight loss drugs

Clinical trials have shown that people using Tirzepatide for weight loss have seen significant reductions in body weight between 15% and 22.5% on average over 72 weeks

OTC products, such as the brands hair loss shampoo and multivitamins, can be purchased outright

The SURMOUNT-1 post-hoc analysis (n=2,542 women), published in Obesity journal 2025, found perimenopausal women on tirzepatide lost 23% of body weight vs 3% on placebo

Addressing Hesitation: What Women Want to Know Before Starting It is completely reasonable to approach a new medication with questions, especially one that involves weekly injections and a meaningful commitment to a treatment protocol